Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446745 | 0.91 | KMT2A (0.57) | ALDH1A1LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL22833247 | 0.90 | LMNA (0.50) | ALDH1A1LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL12190874 | 0.86 | ALDH1A1 (0.61) | ALDH1A1LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL22832408 | 0.85 | ALDH1A1 (0.59) | ALDH1A1LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL7094853 | 0.85 | ADRB2 (0.54) | ALDH1A1LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL5962151 | 0.84 | TSHR (0.63) | ALDH1A1LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL5663225 | 0.83 | NHERF1 (0.48) | ALDH1A1LMNAKMT2ANPC1MEN1 | |
| SCHEMBL9712672 | 0.83 | LMNA (0.62) | ALDH1A1LMNAKMT2ANPC1TDP1 | |
| SCHEMBL13065555 | 0.83 | ALDH1A1 (0.57) | ALDH1A1LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL5664070 | 0.83 | GAA (0.48) | ALDH1A1LMNAKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1620295-A | Preparation of intermediates for the synthesis of antiviral nucleosides | PHARMASSET LTD (BB) | 2005-05-25 | — | — | CN | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| US-20050234246-A1 | Process for producing 2-benzoyloxyacetaldehyde derivative | DAICEL CHEMICAL INDUSTRIES, LTD. | 2005-10-20 | — | — | US | disclosed |
| CN-1620295-A | Preparation of intermediates for the synthesis of antiviral nucleosides | PHARMASSET LTD (BB) | 2005-05-25 | — | — | CN | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885ADRB2 4578/4885 |
| US-20050234246-A1 | Process for producing 2-benzoyloxyacetaldehyde derivative | ALDH1A1, ALDH2, CBR1 | ALDH1A1 1/4885LMNA 2674/4885ADRB2 623/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885ADRB2 4578/4885 |
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | ALDH1A1 1028/4885LMNA 3526/4885ADRB2 3054/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885ADRB2 4578/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885ADRB2 4578/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885ADRB2 4578/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885ADRB2 4578/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | ALDH1A1 14/4885LMNA 2068/4885ADRB2 2550/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | ALDH1A1 1028/4885LMNA 3526/4885ADRB2 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.